Surgery Websites
Immunogenetics & Transplantation Lab »  People »  Director »  Rajalingam Raja, Ph.D., D(ABHI)
Rajalingam Raja, Ph.D., D(ABHI)

Rajalingam Raja, Ph.D., D(ABHI)

Clinical Professor of Surgery
Director, Immunogenetics and Transplantation Laboratory

Contact Information

Immunogenetics and Transplantation Laboratory
University of California at San Francisco
Main Hospital Level B, CPMC Davis Campus
45 Castro Street
San Francisco, CA 94114
Phone: (415) 476-0647
Fax: (415) 476-0379
Open Popup
  • University of Madras, India. B.Sc., 1984
  • Bharathiyar University, India. M.Sc., 1988
  • University of Madras, India. M.Phil., 1989
  • All India Institute of Medical Sciences, India. Ph.D., 1996
  • Postdoctoral Fellow, Stanford University, Stanford 1997-2002

Rajalingam Raja, Ph.D., D(ABHI) is a Clinical Professor in the Department of Surgery and the Director of Immunogenetics and Transplantation Laboratory (ITL) at UCSF. ITL provides cutting edge histocompatibility testing service for solid organ and hematopoietic stem cell transplantation.

Dr. Raja earned his Ph.D. in Immunogenetics at the All India Institute of Medical Sciences, New Delhi in 1997. He was a postdoctoral fellow at Stanford University. Dr. Raja's current research centers on understanding the complex relationship between polymorphic NK cell receptors and HLA class I ligands in human health and disease.

  • Prof. NK Mehra Oration Award 2016, Indian Society for Histocompatibility and Immunogenetics (ISHI), 2016
  • Certificate of Qualification, Histocompatibility Laboratory Director, New York State Department of Health, 2012
  • Histocompatibility Laboratory Director, Department of Public Health, State of California, 2009
  • Clinical Immunology Training Award, FIMSA & IUIS, 1996
  • Clinical Immunology Training Award, Federal of Immunological Societies of Asia-Oceania/International Union of Immunological Societies, 1996
  • Shakuntala Amir Chand prize for the best Ph.D. thesis in Biomedical Sciences in India, Indian Council of Medical Research (ICMR), 1996
  • University First Rank in post-graduation (M.Sc.: Zoology, Biochemicstry, Molecular Biology), Bharathiyar University, Coimbatore, India, 1988

Natural killer (NK) have been implicated in control and clearance of malignant and virally infected cells, regulation of adaptive immune responses, rejection of bone marrow transplants, autoimmunity and the maintenance of pregnancy. Human NK cells largely use a family of Human Leukocyte Antigen (HLA)-specific Killer cell Immunoglobulin-like Receptors (KIR) to recognize and respond to the unhealthy target cells. KIR and HLA loci are both polygenic and substantially polymorphic, and they map to distinct human chromosomes (Chromosomes 19 and 6, respectively).

KIR and HLA gene families segregate independently, yielding many individuals who express KIR receptors for which they lack HLA class I ligands, and vice versa, thus creating human diversity in the number and type of KIR-HLA inherited gene pairs, which potentially could influence the health and disease status of a given individual. The overall goal of our research is to understand the diversity of KIR receptors, HLA ligands, and KIR-HLA gene combinations in populations and their relevance in human health and disease.

Most recent publications from a total of 85
  1. Diego VP, Luu BW, Hofmann M, Dinh LV, Almeida M, Powell JS, Rajalingam R, Peralta JM, Kumar S, Curran JE, Sauna ZE, Kellerman R, Park Y, Key NS, Escobar MA, Huynh H, Verhagen AM, Williams-Blangero S, Lehmann PV, Maraskovsky E, Blangero J, Howard TE. Quantitative HLA-class-II/Factor VIII (FVIII) Peptidomic Variation in Dendritic Cells Correlates with the Immunogenic Potential of Therapeutic FVIII Proteins in Hemophilia A. J Thromb Haemost. 2019 Sep 25. View in PubMed
  2. Roll GR, Webber AB, Gae DH, Laszik Z, Tavakol M, Mayen L, Cunniffe K, Syed S, Hirose R, Freise C, Feng S, Roberts JP, Ascher NL, Stock PG, Rajalingam R. A virtual crossmatch based strategy facilitates sharing of deceased donor kidneys for highly sensitized recipients. Transplantation. 2019 Aug 19. View in PubMed
  3. Gupta N, Henry RG, Kang SM, Strober J, Lim DA, Ryan T, Perry R, Farrell J, Ulman M, Rajalingam R, Gage A, Huhn SL, Barkovich AJ, Rowitch DH. Long-Term Safety, Immunologic Response, and Imaging Outcomes following Neural Stem Cell Transplantation for Pelizaeus-Merzbacher Disease. Stem Cell Reports. 2019 Aug 13; 13(2):254-261. View in PubMed
  4. Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, Confer DL, Eapen M, Fernandez-Vina M, Hartzman R, Maiers M, Marino SR, Mueller C, Perales MA, Rajalingam R, Pidala J. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019 09 19; 134(12):924-934. View in PubMed
  5. Gao Y, Twigg AR, Hirose R, Roll GR, Nowacki AS, Maytin EV, Vidimos AT, Rajalingam R, Arron ST. Association of HLA Antigen Mismatch With Risk of Developing Skin Cancer After Solid-Organ Transplant. JAMA Dermatol. 2019 Mar 01; 155(3):307-314. View in PubMed
  6. Rajalingam R. Diversity of Killer Cell Immunoglobulin-Like Receptors and Disease. Clin Lab Med. 2018 12; 38(4):637-653. View in PubMed
  7. Maruthamuthu S, Rajalingam R, Pandian K, Madasamy S, Manoharan M, Pitchai L, Murugesan A, Mariakuttikan J. Inhibitory natural killer cell receptor KIR3DL1 with its ligand Bw4 constraints HIV-1 disease among South Indians. AIDS. 2018 11 28; 32(18):2679-2688. View in PubMed
  8. Calabrese DR, Florez R, Dewey K, Hui C, Torgerson D, Chong T, Faust H, Rajalingam R, Hays SR, Golden JA, Kukreja J, Singer JP, Greenland JR. Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients. Clin Transplant. 2018 08; 32(8):e13332. View in PubMed
  9. Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, Liu S, Lin Y, Lagisetti C, Chuntova P, Watchmaker PB, Mueller S, Pollack IF, Rajalingam R, Carcaboso AM, Mann M, Sette A, Garcia KC, Hou Y, Okada H. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med. 2018 01 02; 215(1):141-157. View in PubMed
  10. Boudreau JE, Giglio F, Gooley TA, Stevenson PA, Le Luduec JB, Shaffer BC, Rajalingam R, Hou L, Hurley CK, Noreen H, Reed EF, Yu N, Vierra-Green C, Haagenson M, Malkki M, Petersdorf EW, Spellman S, Hsu KC. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation. J Clin Oncol. 2017 07 10; 35(20):2268-2278. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Rajalingam Raja, Ph.D., D(ABHI)
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.


Site Directory